NVDA 125.53 ▼14.01%GOOGL 265.29 ▼2.70%MSFT 484.52 ▼2.77%AMD 424.39 ▼13.25%INTC 51.28 ▼7.97%TSMC 318.71 ▼9.48%AMZN 246.82 ▼4.10%META 560.84 ▼5.93%AAPL 342.56 ▼1.90%PLTR 143.49 ▼6.63%
Markets at last close

Health

a2z-Drafter gains EU certification for CT detection and reporting

·1 min read

a2z Radiology AI has received EU Medical Device Regulation certification for a2z-Drafter, software that detects 182 validated radiological findings across head, chest, abdomen and pelvis CT scans. It is the first AI product certified under the regulation to support both detection and report drafting across those regions. Scarlet NB B.V. certified the software as a Class IIb medical device.

The system identifies findings ranging from acute conditions, including subarachnoid hemorrhage, pneumothorax and bowel obstruction, to abnormalities requiring prompt workup or routine follow-up. Each detected finding receives a priority category that can help providers organize studies for review. Reporting systems can use the findings and supplementary attributes to prepare draft content for a radiologist.

a2z-Drafter is designed to integrate with existing PACS, RIS and worklist systems. It analyzes CT images acquired with or without contrast in adults aged 18 and older. The interpreting physician must independently review the complete study and remains responsible for diagnosis and clinical decisions.

Each finding was evaluated separately against acceptance criteria established in advance. Although a2z Radiology AI has FDA-cleared abdomen-pelvis CT triage software, a2z-Drafter itself is not FDA-cleared or commercially available in the United States.

Originally reported by morningstar.comRead the source →
Related coverage